While several key molecular pathways, such as FLT3, RAS, and TP53 signaling, have been implicated in AML [6, 7, 8], there is an urgent need to clarify new processes that propel AML advancement in order to uncover new treatment targets and enhance patient outcomes. The gene discussed is TP53; the disease is acute myeloid leukemia.